VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Bristol-Myers Squibb

Published: Tuesday, Feb 19, 2008
Bristol-Myers Squibb is a “leading provider of medicines to fight cancer, cardiovascular and infectious diseases—including HIV/AIDS—and serious mental illness.” Bristol-Myers Squibb’s other businesses include Mead Johnson Nutritionals, best known for its Enfamil® line of infant formula, and ConvaTec, which offers high quality ostomy and wound therapeutics products and services.

Abilify®

ABILIFY® is a prescription medicine indicated for the treatment of acute manic and mixed episodes associated with Bipolar I Disorder and for maintaining efficacy in patients with bipolar disorder with a recent manic or mixed episode who had been stabilized and then maintained for at least six weeks.

Experience With Abilify

Healthboards.com: Before You Start Taking Abilify

Tools For Therapy®

This website provides useful information for patients who are being treated with Abilify for Bipolar I Disorder, including a calendar (to keep track of appointments and prescriptions), an automatically generated e-mail Refill Reminder, a body mass index (BMI) calculator, and a mood tracker.

SprycelTM

Sprycel is an oral inhibitor of multiple tyrosine kinases, for the treatment of adults in all phases of chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy.

Blogspotter

The Cancer Blog: CML Patients who Have Stopped Responding to Gleevec Have Options

In this blog, readers discuss American Society of Hematology study results which demonstrate that treatment with Sprycel (dasatinib) provides better outcomes compared to administering higher doses of Gleevec (imatinib) in patients with chronic myeloid leukemia (CML). In the clinical trial, the patients were either treated with Sprycel or increased doses of Gleevec to see who had the better response.

Clinical Trials

Belatacept Conversion Trial in Renal Transplantation Study Type: Interventional

Age/Gender Requirement: 18 years+ (male/female)

Notes: The purpose of this study is to learn if conversion to belatacept from cyclosporine or tacrolimus will preserve kidney function in people who have had a kidney transplant. The safety of this treatment is also studied.

An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy

Study Type:
Interventional

Age/Gender Requirement: 18 years+ (male/female)

Notes: This study assesses the changes in synovial tissue before and after treatment with Abatacept in subjects with RA who remained on their background disease modifying antiarthritis medications but who have failed previous therapy with anti-TNF (tumor necrosing factor) blocking agents.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Bridging the Gaps Around Oncology Biosimilars: Assessing the Potential Impact of Emerging Agents to PracticeSep 29, 20181.5
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x